Citadel Advisors
STOK icon

Citadel Advisors’s Stoke Therapeutics STOK Stock Holding History

Citadel Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Sell
10,000
-11,400
-53% -$366K ﹤0.01% 10932
2026
Q1 		$697K Buy
21,400
+12,000
+128% +$394K ﹤0.01% 8502
2025
Q4 		$298K Buy
+9,400
New +$283K ﹤0.01% 10167
2025
Q2 		– Sell
-34,300
Closed -$228K – 14980
2025
Q1 		$228K Buy
34,300
+25,400
+285% +$237K ﹤0.01% 10191
2024
Q4 		$98.2K Sell
8,900
-300
-3% -$3.69K ﹤0.01% 11510
2024
Q3 		$113K Buy
9,200
+1,000
+12% +$14.2K ﹤0.01% 10957
2024
Q2 		$111K Sell
8,200
-41,100
-83% -$555K ﹤0.01% 10769
2024
Q1 		$666K Buy
49,300
+48,700
+8,117% +$295K ﹤0.01% 7770
2023
Q4 		$3.16K Sell
600
-3,800
-86% -$16.2K ﹤0.01% 13624
2023
Q3 		$17.3K Sell
4,400
-8,200
-65% -$53.9K ﹤0.01% 12736
2023
Q2 		$134K Buy
12,600
+10,900
+641% +$116K ﹤0.01% 10499
2023
Q1 		$14.2K Sell
1,700
-2,700
-61% -$24.4K ﹤0.01% 13324
2022
Q4 		$40.6K Buy
+4,400
New +$45.8K ﹤0.01% 12398
2021
Q3 		– Sell
-14,300
Closed -$481K – 14614
2021
Q2 		$481K Buy
+14,300
New +$506K ﹤0.01% 10141
2021
Q1 		– Sell
-4,300
Closed -$266K – 13694
2020
Q4 		$266K Buy
+4,300
New +$197K ﹤0.01% 9271

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's STOK Position: Q2 2026 in Review

Citadel Advisors increased its Stoke Therapeutics (STOK) stake by 298% in Q2 2026, buying an estimated $11.8M and bringing the position to 489,301 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Citadel Advisors first reported a position in STOK in Q2 2019 and has held it in 23 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Citadel Advisors held 489,301 shares of Stoke Therapeutics worth $16M as of Q2 2026.
  • Citadel Advisors bought 366,279 Stoke Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Stoke Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2878 holding.
  • Citadel Advisors first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.